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a low-calorie (low-lipid) diet resulted in a reduction in this 
fatty acid concentration to the level observed in controls. 
Cyclopropaneoctanoic acid 2-hexyl was also found in foods 
derived from animal fat. Serum concentrations of triacylg-
lycerols in the analyzed groups followed a pattern similar to 
that for serum cyclopropaneoctanoic acid 2-hexyl, and these 
variables were positively correlated with each other among 
the studied groups. Patients with hypertriglyceridemia-
related conditions presented with elevated serum levels of 
cyclopropaneoctanoic acid 2-hexyl. Our findings suggest 
that its high serum level is related to high serum triacylglyc-
erol concentrations rather than to body mass or BMI.
Keywords Cyclopropaneoctanoic acid 2-hexyl · 
Obesity · Chronic kidney disease · Hypertriglyceridemia
Abbreviations
BMI  Body mass index
GC–MS  Gas chromatography–mass spectrometry
CFA  Cyclopropane fatty acid
FA  Fatty acid
CPOA2H  Cyclopropaneoctanoic acid 2-hexyl
SFA  Saturated fatty acid
MUFA  Monounsaturated fatty acid
PUFA  Polyunsaturated fatty acid
CKD  Chronic kidney disease
FAME  Fatty acid methyl ester
SEM  Standard error of the mean
TAG  Triacylglycerol
Introduction
Cyclopropane fatty acids (CFA) are found in phospholip-
ids and glycolipids of cell membranes from many bacterial 
Abstract We recently reported the presence of various 
cyclopropane fatty acids—among them, cyclopropaneocta-
noic acid 2-hexyl—in the adipose tissue of obese women. 
The aim of this study was to verify whether the presence 
of cyclopropaneoctanoic acid 2-hexyl in human serum was 
associated with obesity or chronic kidney disease (both 
being related to dyslipidemia), and to find potential associa-
tions between the serum level of this compound and specific 
markers of the these conditions. The serum concentration of 
cyclopropaneoctanoic acid 2-hexyl was determined by gas 
chromatography–mass spectrometry (GC–MS) in non-obese 
controls, obese patients, obese patients after a 3-month low-
calorie diet, and individuals with chronic kidney disease. 
Obese patients and those with chronic kidney disease pre-
sented with higher serum levels of cyclopropaneoctanoic 
acid 2-hexyl than controls. Switching obese individuals to 
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species, and likely play a role in the pathogenesis of bac-
terial infections [1]. These fatty acids (FA) have also been 
found in certain eukaryotes, including protozoa [2] and 
plants [3, 4]. However, few studies have documented the 
presence of CFA in animals [5–7]. We recently found four 
CFA—cyclopropaneoctanoic acid 2-hexyl, cyclopropa-
neoctanoic acid 2-octyl, cyclopropanenonanoic acid and 
2-[[2-[(2-ethylcyclopropyl)methyl]cyclopropyl]methyl] 
acid—in the adipose tissue of obese women [8]. Cyclopro-
paneoctanoic acid 2-hexyl (CPOA2H), also referred to as 
9,10-methylene hexadecanoic acid, was the most abundant 
CFA, as well as the only CFA detectable in their serum [8]. 
The results of previous studies suggest that CFA may play 
an important role in the human body, given their regulatory 
properties such as control of cyclooxygenase activity [9], 
actomyosin ATPase [10], protein kinase C-ɛ [11], stearoyl-
CoA desaturase [12] and inflammation [13]. CFA present 
in bacteria and plants are synthesized from unsaturated FA 
due to involvement of cyclopropane synthase, an enzyme 
catalyzing the addition of the methylene group from 
S-adenosylmethionine to the double bond of FA precursors 
[1, 14].  To date, however, this enzyme has not been iden-
tified in animals. Since our previous research [8] included 
adipose tissue and serum from obese women, we thought 
that it would be interesting to examine whether the pres-
ence of CFA was obesity-specific. To this end, we deter-
mined serum levels of CPOA2H in non-obese controls, 
obese patients, obese persons after a 3-month low-calorie 
diet and individuals with chronic kidney disease (CKD), 
i.e. with a disease related to dyslipidemia. We also looked 
for potential associations between the levels of CPOA2H, 
serum concentrations of lipids, and other biochemical and 
anthropometrical parameters of the study subjects.
Materials and Methods
Patients
The study included 76 women. Ten obese patients were 
examined at an ambulatory surgical  facility as a part of the 
qualification for bariatric surgery performed at the Depart-
ment of General, Endocrine and Transplant Surgery, Medical 
University of Gdansk (Poland). Another 29 obese patients 
were on a low-calorie diet (1000–1200 kcal/day, high protein 
and low fat and carbohydrate content) for 3 months prior to 
the study. The mean weight loss in this group was 9.75 kg. 
Patients with CKD are another population in whom dyslipi-
demia is a common finding. Although the etiology of lipid 
disorders observed in individuals with CKD is different from 
that in obese patients, the major disturbances, including ele-
vated triacylglycerol concentration, are essentially similar. 
In addition, like obese subjects, patients with CKD present 
with clearly increased cardiovascular risk. Consequently, 15 
women were selected from a pool of patients who had been 
subjected to peritoneal dialysis due to end-stage renal fail-
ure at the Department of Nephrology, Transplantology and 
Internal Medicine, Medical University of Gdansk. The con-
trol group included 22 healthy non-obese volunteers who 
were referred for an annual health check-up. The patients’ 
serum was obtained retrospectively from a sample bank, 
and clinical and demographic characteristics were extracted 
from a clinical database. The protocol of the study was 
approved by the local bioethics committee at the Medical 
University of Gdan´sk (protocol nos. NKEBN/475/2012 and 
NKEBN/614/2013-2014), and patients gave their informed 
consent to use of their clinical data and analyses performed 
in the study. The study protocol adhered to the tenets of the 
Declaration of Helsinki of the World Medical Association. 
Characteristics of the study participants are presented in 
Table 1. A Tanita scale was used to estimate the parameters 
of body constitution, including body weight, body height 
and BMI. BMI was calculated from the following formula: 
BMI (kg/m2) = body weight (kg)/body height (m)2. Blood 
samples for determining basic laboratory parameters, such as 
serum albumin, C-reactive protein, total cholesterol, and tria-
cylglycerols, were collected from patients after an overnight 
fast. All laboratory parameters were determined at the Cen-
tral Clinical Laboratory, Medical University of Gdansk. The 
remaining aliquots of serum were stored at −80 °C for fatty 
acid composition analysis.
Gas Chromatography–Mass Spectrometry (GC–MS) 
Analysis of FA
Total lipids were extracted from patient serum and from 
cow’s milk, porcine, chicken, trout fat, and rapeseed oil 
using the method described by Folch et al. [21]. Subse-
quently, FA were derivatized to FA methyl esters (FAME) 
using 10 % boron trifluoride-methanol solution. FA profiles 
in the adipose tissue and serum lipids were analyzed with 
the GCMS QP-2010SE unit (Shimadzu, Kyoto, Japan), 
as described previously [8]. In our recent study, we con-
firmed the identification of CPOA2H by derivatization of 
FA to picolinyl esters, followed by GC–MS analysis [8]. 
The presence of this FA in serum was further confirmed 
using a CPOA2H standard obtained from Matreya, LLC 
(State College, PA, USA). Concentrations of individual FA, 
including CPOA2H, were calculated based on the amount 
of added internal standard and volume of serum used for 
the procedure.
Statistical Analysis
The statistical significance of intergroup differences was 
determined with one-way analysis of variance (ANOVA), 
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and the Tukey post hoc test was used for multiple compari-
sons. Inter-group differences were considered significant at 
p < 0.05. All data are presented as means ± standard errors 
of the mean (SEM). Normality was verified with the Shap-
iro–Wilk test. The relationships between pairs of variables 
were determined on the basis of linear regression analysis. 
All calculations were conducted using SigmaPlot for Win-
dows, version 11.0 (2008; Systat Software Inc).
Results
Obese subjects and CKD patients differed from the con-
trols in terms of whole serum lipids FA concentrations. 
Obese women presented with higher serum concentrations 
of saturated FA (SFA) and monounsaturated FA (MUFA) 
(Table 2). Obese women after a low-calorie diet did not dif-
fer significantly from controls in terms of fatty acid con-
centrations (Table 2). Patients with chronic kidney disease 
presented with lower n-6 PUFA levels than the controls 
(Table 2). Serum concentrations of CPOA2H were signifi-
cantly higher in morbidly obese women than in non-obese 
subjects (24.2 ± 3.07 vs. 15.3 ± 1.69 µmol/L, p < 0.05; 
Fig. 1). Serum levels of CPOA2H in obese women after 
a low-calorie diet were similar to those found in the con-
trols (16.7 ± 1.15 vs 15.3 ± 1.69 µmol/L, Fig. 1). CKD 
patients presented with significantly higher serum con-
centrations of CPOA2H than did controls (21.1 ± 1.92 vs 
15.3 ± 1.69 μmol/L, p < 0.05; Fig. 1).
To identify the potential pathophysiological role of 
CPOA2H serum concentration, we also compared study 
groups in terms of selected anthropometric and biochemi-
cal parameters (Table 3). Since CPOA2H was originally 
found in serum from obese women [8], we first analyzed 
the BMI of our subjects. Both serum CPOA2H and BMI 
were significantly higher in obese women than in controls. 
However, while the BMI of obese women who had been 
maintaining a low-lipid diet was only about 3.5 % lower 
than prior to diet implementation, their serum CPOA2H 
concentrations were similar to those found in non-obese 
controls, implying that CPOA2H found in our subjects 
might originate from food. To verify this hypothesis, we 
determined the content of this FA in selected high-fat foods. 
CPOA2H was found in cow’s milk, porcine, chicken and 
trout fat, but not in rapeseed oil (Table 4). CKD patients, 
whose BMI was similar to that of the controls, presented 
with significantly higher CPOA2H levels. As shown in 
Table 3, serum concentrations of triacylglycerols (TAG) 
followed a pattern similar to serum CPOA2H levels. We 
conducted linear regression analysis to determine the exact 
relationship between CPOA2H and various anthropometric 
and laboratory parameters including age, BMI, albumin, 


























































































































































































































































































































































































































































































































































































































































































































870 Lipids (2016) 51:867–873
1 3
studied groups of patients. We found strong positive corre-
lations between CPOA2H and serum TAG in obese subjects 
and controls (Table 5). We also found positive correlations 
between CPOA2H and serum cholesterol in both groups of 
obese patients (Table 5).
Discussion
The FA profile in human serum is an established determi-
nant of metabolic and cardiovascular risk [15]. A recent 
identification of CFA in human adipose tissue and blood 
[8] stimulated questions about their physiological role. 
We recently found CPOA2H in the serum of patients with 
obesity, a disease associated with dyslipidemia, inflamma-
tion and increased cardiovascular risk. Consequently, we 
decided to compare the serum concentrations of this FA in 
obese subjects and non-obese controls, and searched for 
associations between this parameter and selected markers of 
metabolic disorders. In addition, our study included individ-
uals with CKD, a disease which is also associated with vari-
ous lipid disorders and increased cardiovascular risk [16], 
but usually not with excess body weight. Obese women pre-
sented with higher CPOA2H levels than non-obese controls. 
Table 2  Fatty acid concentrations in the whole serum lipids of the study subjects
Data are presented as mean ± SEM
* p < 0.01; # p < 0.05 indicates a statistically significant difference compared to controls
Fatty acid Controls (μmol/L) Obese patients  
(μmol/L)
Obese patients  
after diet (μmol/L)
Patients with chronic kidney  
disease (μmol/L)
12:0 15.1 ± 1.54 24.2 ± 6.49 16.4 ± 1.68 15.7 ± 1.75
14:0 93.5 ± 9.04 188 ± 59.2# 94.1 ± 7.29 115 ± 11.9
15:0 26.1 ± 2.21 31.7 ± 6.03 25.8 ± 1.71 26.8 ± 2.28
16:0 1569 ± 125 2393 ± 482# 1820 ± 92.7 1697 ± 156
17:0 23.4 ± 1.78 29.7 ± 5.91# 21.7 ± 1.02 28.8 ± 2.68#
18:0 525 ± 42.2 668 ± 135 491 ± 24.7 584 ± 69.2
19:0 3.48 ± 0.32 3.73 ± 0.78 3.08 ± 0.25 3.13 ± 0.37
20:0 11 ± 0.84 15.8 ± 3.90 11.2 ± 0.64 13.4 ± 1.40
21:0 3.78 ± 0.34 3.65 ± 0.46 4.31 ± 0.31 3.06 ± 0.29
22:0 17.4 ± 1.12 19.6 ± 3.37 18.2 ± 1.02 16.3 ± 1.58
23:0 6.77 ± 0.54 7.38 ± 1.48 6.57 ± 0.33 6.25 ± 0.85
24:0 16.8 ± 1.09 18.1 ± 2.92 17.1 ± 0.93 14.6 ± 1.24
SFA 2311 ± 14.9 3403 ± 57.7# 2530 ± 10.3 2525 ± 19.7
14:1 4.74 ± 0.66 11.6 ± 4.6# 4.76 ± 0.46 6.26 ± 0.81
16:1 206 ± 21.7 386 ± 74.9* 267 ± 22.1 265 ± 30.1
18:1 1578 ± 132 2445 ± 470# 1869 ± 107 1959 ± 223
20:1 12.0 ± 1.21 19.0 ± 4.59 13.8 ± 1.06 19.5 ± 1.83*
24:1 14.2 ± 1.49 19.6 ± 3.58 14.2 ± 0.74 14.2 ± 1.43
MUFA 1815 ± 31.1 2880 ± 110# 2169 ± 25.3 2263 ± 50.5
18:2n-6 1742 ± 127 1778 ± 2370 1532 ± 91.6 1257 ± 107#
20:4n-6 376 ± 40.1 439 ± 71.9 430 ± 22.1 230.85 ± 19.8#
20:3n-6 82.7 ± 8.01 137 ± 18.2* 92.5 ± 7.39 67.2 ± 7.24
20:2n-6 16.1 ± 2.80 17.0 ± 1.89 12.8 ± 0.97 15.2 ± 1.39
22:5n-6 6.26 ± 0.66 8.14 ± 1.32 6.94 ± 0.46 4.23 ± 0.41#
22:4n-6 10.7 ± 1.65 13.8 ± 2.23 10.3 ± 0.65 4.88 ± 0.59#
PUFAn-6 2234 ± 28.9 2393 ± 53.8 2084 ± 19.1 1579 ± 22.1#
18:3n-3 19.2 ± 2.26 42.5 ± 10.9* 21.9 ± 2.41 15.3 ± 1.70
20:5n-3 59.1 ± 7.34 72.2 ± 19.2 60.0 ± 6.04 53.5 ± 5.09
20:4n-3 8.02 ± 1.08 11.6 ± 1.71 6.78 ± 0.79 8.80 ± 0.96
22:6n-3 96.0 ± 13.1 83.7 ± 11.7 106 ± 7.95 71.5 ± 6.60
22:5n-3 26.5 ± 2.91 34.0 ± 5.65 25.2 ± 1.63 20.6 ± 1.58
PUFAn-3 209 ± 5.02 244 ± 9.20 220 ± 3.17 170 ± 2.42
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However, excess body weight did not seem to be a principal 
determinant of the serum concentration of this FA: although 
obese patients who had been subjected to a 3-month low-
calorie diet still differed from non-obese controls in terms of 
BMI, they showed similar CPOA2H concentrations. In con-
trast, patients with CKD showed no significant difference 
from controls in terms of BMI, despite significantly higher 
serum CPOA2H levels. Lastly, we found no significant cor-
relation between serum CPOA2H and BMI.
Since statistically significant correlations were found 
between serum CPOA2H and TAG levels, one can specu-
late that CPOA2H interacts with the endogenous synthesis 
of lipids—for instance, by influencing transcription factors 
involved in this process, as reported previously for other 
FA [17–19]. However, this hypothesis must be verified 
empirically, for example, by treating lipogenic cells with 
this FA. Importantly, the correlation between serum levels 
of CPOA2H and TAG may also reflect dietary intake of this 
FA with high-fat foods. Caligiani et al. recently reported 
the presence of an 18-carbon CFA in cow’s milk and dairy 
products [20]. In our previous study, we found CPOA2H 
in the TAG fraction of human blood [8], which suggests 
that this FA may originate from chylomicrons transport-
ing ingested lipids. This hypothesis is also supported by 
the fact that obese individuals subjected to a 3-month low-
calorie (low-lipid) diet presented with significantly lower 
serum levels of CPOA2H. Furthermore, the findings pre-
sented here are consistent with the results of our previous 
study [8], in which we found decreased CPOA2H levels 
in the adipose tissue of rats that had been provided 50 % 
of the total amount of food consumed by the controls for a 
period of 1 month. The fact that this FA has been found in 
certain high-fat foods commonly consumed in our country 
also supports this hypothesis, although we should note that 
the dietary origin of CPOA2H in the serum of patients is 
speculation on our part. Interestingly, patients with CKD—
albeit without obesity—presented with high concentrations 
of CPOA2H. The diet recommended in CKD, however, is 
not rich in fat (Table 1). Therefore, high serum concentra-
tions of CPOA2H in CKD patients seem to be associated 
rather with increased serum levels of TAG.
The relevance of altered serum concentrations of 
CPOAH2 remains unclear. Given the positive correla-
tions between concentrations of this FA, TAG and choles-
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Fig. 1  Serum concentrations of cyclopropaneoctanoic acid 2-hexyl 
in study subjects, including non-obese controls, obese patients, 
obese subjects after a 3-month low-calorie (low-lipid) diet and indi-
viduals with chronic kidney disease (CKD). Data are presented as 
mean ± SEM. *p < 0.05 compared to the controls
Table 3  Selected characteristics of the study participants
Data are presented as mean ± SEM
* p < 0.01 indicates statistically significant difference compared to controls
Controls Obese patients Obese patients after diet Patients with chronic  
kidney disease
Age (years) 35.6 ± 2.62 46.4 ± 3.52 40.6 ± 1.75 55.1 ± 3.74*
BMI (kg/m2) 22.6 ± 0.67 43.3 ± 1.88* 40.7 ± 1.01* 26.5 ± 1.35
Albumin (g/L) 41.4 ± 0.74 40.0 ± 1.37 37.0 ± 0.93 39.6 ± 1.38
CRP (mg/L) 0.75 ± 0.16 11.8 ± 3.21* 5.71 ± 0.79* 4.72 ± 0.88*
Total cholesterol (mg/dL) 183 ± 5.42 188 ± 13.4 184 ± 7.92 227 ± 10.1*
Triacylglycerols (mg/dL) 72.8 ± 9.06 180 ± 24.1* 122 ± 8.20* 145 ± 17.8*
Table 4  Cyclopropaneoctanoic 
acid 2-hexyl content in 
commonly consumed high-fat 
foods
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individuals and patients with kidney disease, we can specu-
late that CPOAH2 negatively affect the cellular metabolism 
of lipids. However, elevated levels of CPOA2H in these 
groups of patients may also represent an adaptive response. 
In vitro studies of hepatocytes and adipose tissue cells are 
needed to answer this question.
Conclusions
This study showed that hypertriglyceridemia observed 
during the course of diseases such as CKD and obesity 
is associated with an increase in serum concentration of 
CPOA2H. Future studies should elucidate whether this 
uncommon FA may influence cellular metabolism in 
humans.
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